Pan American Silver Corp. (PAAS)

Achilles Therapeutics Stock Forecast

Stock Price Forecast

The 4 analysts that cover Achilles Therapeutics stock have a consensus rating of "Buy" and an average price target of $32.25, which forecasts a 1.86% increase in the stock price over the next year. The lowest target is $23 and the highest is $46.

Price Target: $32.25 (+1.86%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$23	$32.25	$32	$46
Change	-27.35%	+1.86%	+1.07%	+45.29%

* Price targets were last updated on Jul 15, 2025.

Analyst Ratings

The average analyst rating for Achilles Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	1	1	1	1	1	1
Buy	2	2	2	2	2	2
Hold	2	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	4	4	4	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Cosmos Chiu CIBC	CIBC	Buy Maintains $39 → $46	Buy	Maintains	$39 → $46	+45.29%	Jul 15, 2025
Cosmos Chiu CIBC	CIBC	Buy Maintains $42 → $39	Buy	Maintains	$42 → $39	+23.18%	May 13, 2025
Cosmos Chiu CIBC	CIBC	Buy Maintains $38 → $42	Buy	Maintains	$38 → $42	+32.66%	May 8, 2025
Ovais Habib Scotiabank	Scotiabank	Buy Maintains $29 → $32	Buy	Maintains	$29 → $32	+1.07%	Apr 14, 2025
Craig Hutchison TD Securities	TD Securities	Strong Buy Maintains $25 → $28	Strong Buy	Maintains	$25 → $28	-11.56%	Feb 27, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

3.18B

Increased by 12.63%

from 2.82B

Revenue Next Year

3.30B

Increased by 3.78%

from 3.18B

EPS This Year

1.25

Increased by 308.19%

from 0.31

EPS Next Year

2.01

Increased by 60.26%

from 1.25

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	1.34B	1.63B	1.49B	2.32B	2.82B	3.18B	3.30B	3.30B
Revenue Growth	-0.88%	21.96%	-8.46%	54.95%	21.71%	12.63%	3.78%	0.06%
EPS	0.85	0.46	-1.62	-0.32	0.31	1.25	2.01	1.50
EPS Growth	53.99%	-45.67%	-	-	-	308.19%	60.26%	-25.05%
Forward PE	-	-	-	-	-	25.28	15.77	21.04
No. Analysts	-	-	-	-	-	8	8	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	3.5B	3.7B	4.4B
Avg	3.2B	3.3B	3.3B
Low	2.9B	2.9B	2.8B

Revenue Growth

Revenue Growth	2025	2026	2027
High	25.5%	16.3%	32.1%
Avg	12.6%	3.8%	0.1%
Low	2.2%	-8.0%	-15.9%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	1.48	3.42	2.68
Avg	1.25	2.01	1.50
Low	0.97	1.33	0.67

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	382.5%	173.3%	33.4%
Avg	308.2%	60.3%	-25.1%
Low	216.2%	6.4%	-66.8%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.